Se rendre au contenu

Supercritical CO₂ solutions for industrial applications

Vision & Mission

Biotech One is a deep tech technology provider delivering clean and competitive supercritical CO₂–based solutions to address critical industrial challenges in  nanoparticle encapsulation, extraction, and sterile processing.

Our solutions are designed with a strong focus on process robustness, scalability, and industrial readiness, enabling reliable deployment from R&D to full-scale manufacturing.

We operate as an industrial technology enabler, designing and delivering deployable process platforms that allow manufacturers to industrialize supercritical CO₂ technologies within their own production environments.

Contact us

Markets & applications

Biotech One’s supercritical CO₂ technologies are designed for industrial markets with strong technical and regulatory constraints, and are applied across the following segments:

  • Pharmaceuticals & biotechnology – encapsulation, formulation, clean processing
  • Nutraceuticals, Food products, & cosmetics – extraction, fractionation, solvent-free processing
  • Medical devices & healthcare products – sterilization and low-temperature processing
  • Energy, renewables & bio-based materials – bio-oils, waste valorization, advanced materials

Across these segments, our platforms enable:

  • Extraction and fractionation of sensitive compounds
  • Encapsulation and nanoparticle formulation
  • Sterilization and clean processing

Our Products & services

Integrated solutions for encapsulation, extraction and sterilization using sc CO2 technology

Research & Innovation


R&D studies and proof-of-concept (PoC)

Feasibility studies and experimental validation 

Process optimization


Scale-up


Co-development​

Joint development programs to adapt supercritical CO₂ technologies to specific applications and scale-up requirements.

Development & production


Equipment

Equipment
Design and sale of industrial systems, including the EncapX® encapsulation system for continuous production of lipid nanoparticles and nanoliposomes.

Licensing & support

Technology licensing, process transfer, and technical support to enable integration into industrial environments.

Limited pilot and demonstration batches of extracted or encapsulated ingredients

Ingredients may be produced to support PoC, process optimization, and industrial validation

 R&D & Technology platforms

R&D

Biotech One combines applied R&D, academic collaboration, and industrial engineering to support the transition from proof-of-concept to industrial deployment.


The company operates within a strong scientific and institutional ecosystem and is actively involved in European R&D programs supporting the industrialization of clean and sustainable processing technologies.

Discover more

Our technology platforms:


  • EncapX® – Continuous encapsulation system for lipid nanoparticles and nanoliposomes
  • ExtraX® – Clean extraction and fractionation platform
  • SteriX® – CO₂-based sterilization and decontamination processes

All platforms are conceived as industrial tools, designed for robustness, scalability, and compatibility with regulated environments.

Key milestones & company history


Business & Funding

Research & Technology

2022

Creation of Biotech One – Initial capital €445k

Award of the BPI “French Tech Grant” (€25k)

supporting R&D on supercritical CO₂ encapsulation processes

2023

First commercial contracts in chemistry and cosmetics industries

R&D to develop patents, proprietary know-how, and industrial processes.

2024

Technology validation through commercial collaborations with major industrial groups

Patent Extraction / Fractionation

Acquisition of an exclusive exploitation license for patents covering continuous extraction from algae without any drying step.

2025

First commercial order for an EncapX automated system

EncapX patent - validation


Continuous millifluidic nanoliposome encapsulation process and equipment


FUNDRAISING

 Entry of RSI (Région Sud Investissement) and CAAP Crédit Agricole into the company’s capital

Laureate HORIZON EUROPE Grant (Alliance) 

(48 months – total project €8.75M – Biotech One share €445k)

2026

Commercial scale-up and industrial deployment 

R&D consolidation and full-scale validation within EU projects

Team

Core Team & Experts

Fabien BALMECEO/CTO

CTO/CEO. Master Degree in engineering. Over 35 years of experience as senior executive (Siemens) and serial entrepreneur with a healthcare exit.

Dr. Elissandro KLEIN

R&D Project Manager - Ph.D. Chemical Engineering, Supercritical fluids expert.


Marcelo KRAVICZ

PhD, Nanomedicine

Expert in RNA delivery & scalable nanoencapsulation.

Sandra ROBELET

Scientific Ambassador, PhD in Neurosciences, 20+ years of exp. across CRO, biopharma, and business development

​Jade SIMON

Biology Engineering

Market Consultant for microalgae-based ingredients.


Christophe

MBA, sterilization applications and industrial deployment. 20+ years exp. in medical devices development. 

Scientific Advisory Board

Pr. Elisabeth BADENS

​PhD, Chemical engineering. Editor-in-Chief, Journal of Supercritical Fluids. Full Professor at Aix Marseille University. TEDx speaker.


Pr. Feral TEMELLI

Nutraceutical Expert

Associate Editor, JSF. Focus on natural biological resources processing.



​Iago Dominguez TELES

PhD Microalgae Expert

Research Manager at Wageningen University. Microalgae bioprocessing & scale-up expert.Supports algae sourcing.



Dr Omar SALMAN

Pharma, Ph.D. in Chemical Engineering. Awarded for his role in developing key components of the Pfizer-BioNTech COVID-19 vaccine.

Shareholders & Governance

Thierry Bourdillon

Représentant de CAAP Création (Crédit Agricole). Responsable de participations  chez CAAP Création

https://www.capital-innovation.ca-alpesprovence.fr/investisseur/

Benjamin BESSAC 

Représentant de RSI - Région Sud Investissement . Chargé d'investissements 

www.regionsudinvestissement.com

We create the perfect
tailored solution for you